Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#3070 Activity and Safety of Avelumab in Merkel Cell Carcinoma: Our Experience
Introduction: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. The use of checkpoint inhibitors has shown good results in the treatment of advanced MCC. Avelumab is a PD-L1 inhibitor able to prevent the inactivation of the T lymphocytes. We report a serie of consecutive MCC cases treated with Avelumab in two centres
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Giuffrida D
Authors: Puliafito I, Sciacca D, Bonasera A, Blanco G, Iacono F,
Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Rodriguez-Freixinos V
Authors: Rodriguez-Freixinos V, Chan D, Doherty M, Wasson K, Iscoe N,
Keywords: Poorly differentiated, G3 NECs, Avelumab, Immunotherapy,
#2796 Avelumab for Advanced Merkel Cell Carcinoma in the Netherlands; A Nationwide Survey
Introduction: Merkel cell carcinoma (MCC) is a rare, tumor of the skin associated with high recurrence rates and poor survival. Clinical trials have shown activity of checkpoint inhibitors targeting programmed death-(ligand)-1 (PD-(L)1). Avelumab is the only PD-L1 inhibitor that has been approved in the Netherlands for advanced/metastatic MCC (mMCC).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Levy S
Authors: Levy S, Aarts M, Eskens F, Keymeulen K, Been L,
Keywords: Merkel Cell Carcinoma, Avelumab, PD-L1,
Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Weber M
Authors: Fottner C, Apostolidis L, Ferrata M, Krug S, Michl P,
Keywords: NEC, NEN G3, check-point inhibitor, Avelumab, anti-PD-L1-antibody, immunotherapy,
#2774 Metastatic Merkel Cell Carcinoma Associated Paraneoplastic Hyponatraemia: Response to Avelumab
Introduction: Merkel cell carcinoma (MCC) is rare, encompassing primary cutaneous neuroendocrine carcinoma.It has an aggressive natural history, and exhibits high response rates to radiotherapy & chemotherapy but often of short duration.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Demirel S
Authors: Saunders E, Demirel S, Kim S, Skelly R, Mukesh M,
Keywords: merkel cell carcinoma, paraneoplastic syndrome, hyponatraemia,